Association of plasma ceramides and sphingomyelin with VLDL apoB-100 fractional catabolic rate before and after rosuvastatin treatment

Theodore Wai Ng, Esther Ooi, Gerald Watts, Dick Chan, P.J. Meikle, Hugh Barrett

    Research output: Contribution to journalArticle

    6 Citations (Scopus)
    104 Downloads (Pure)

    Abstract

    Copyright © 2015 by the Endocrine Society. Introduction: The objective of the study was to examine post hoc associations between plasma sphingolipids and lipoprotein kinetics in men with the metabolic syndrome after rosuvastatin treatment. Materials and Methods: Plasma sphingolipid profiling, determined by tandem mass spectrometry, was performed in a randomized, double-blind, triple-crossover trial (n = 12) of 5-week treatment periods with placebo or rosuvastatin (10 or 40 mg/d) with 2-week washouts between treatments. Results and Discussion: Baseline plasma ceramides were associated with very low-density lipoprotein (VLDL) apolipoprotein (apo)-B-100 concentration (r = 0.58, P <.05) and inversely with VLDL apoB-100 fractional catabolic rate (FCR; r = -0.67, P = .02). Posttreatment changes with rosuvastatin (40 mg/d) in plasma ceramides were inversely associated with VLDL apoB-100 FCR (r = -0.62, P = .03) independent of changes in plasma triglycerides, cholesterol, and low-density lipoproteincholesterol. By contrast, baseline and postrosuvastatin treatment plasma sphingomyelin levels were not associated with apoB-100 kinetics. Plasma ceramides and sphingomyelin were not associated with the kinetics or concentrations of high-density lipoprotein apoA-I, and low-density lipoprotein apoB. In the metabolic syndrome, the ability of rosuvastatin to increase VLDL apoB-100 FCR may reflect ceramide-specific mechanistic actions and/or sphingolipid exchange.
    Original languageEnglish
    Pages (from-to)2497-2501
    JournalJournal of Clinical Endocrinology and Metabolism
    Volume100
    Issue number6
    DOIs
    Publication statusPublished - Jun 2015

    Fingerprint

    Apolipoprotein B-100
    Sphingomyelins
    VLDL Lipoproteins
    Ceramides
    Plasmas
    Sphingolipids
    Therapeutics
    Kinetics
    Apolipoprotein A-I
    Apolipoproteins B
    HDL Lipoproteins
    Tandem Mass Spectrometry
    Rosuvastatin Calcium
    LDL Lipoproteins
    Cross-Over Studies
    Lipoproteins
    Mass spectrometry
    Triglycerides
    Cholesterol
    Placebos

    Cite this

    @article{5bbcaee15bc14802917b66e335ebe3e2,
    title = "Association of plasma ceramides and sphingomyelin with VLDL apoB-100 fractional catabolic rate before and after rosuvastatin treatment",
    abstract = "Copyright {\circledC} 2015 by the Endocrine Society. Introduction: The objective of the study was to examine post hoc associations between plasma sphingolipids and lipoprotein kinetics in men with the metabolic syndrome after rosuvastatin treatment. Materials and Methods: Plasma sphingolipid profiling, determined by tandem mass spectrometry, was performed in a randomized, double-blind, triple-crossover trial (n = 12) of 5-week treatment periods with placebo or rosuvastatin (10 or 40 mg/d) with 2-week washouts between treatments. Results and Discussion: Baseline plasma ceramides were associated with very low-density lipoprotein (VLDL) apolipoprotein (apo)-B-100 concentration (r = 0.58, P <.05) and inversely with VLDL apoB-100 fractional catabolic rate (FCR; r = -0.67, P = .02). Posttreatment changes with rosuvastatin (40 mg/d) in plasma ceramides were inversely associated with VLDL apoB-100 FCR (r = -0.62, P = .03) independent of changes in plasma triglycerides, cholesterol, and low-density lipoproteincholesterol. By contrast, baseline and postrosuvastatin treatment plasma sphingomyelin levels were not associated with apoB-100 kinetics. Plasma ceramides and sphingomyelin were not associated with the kinetics or concentrations of high-density lipoprotein apoA-I, and low-density lipoprotein apoB. In the metabolic syndrome, the ability of rosuvastatin to increase VLDL apoB-100 FCR may reflect ceramide-specific mechanistic actions and/or sphingolipid exchange.",
    author = "Ng, {Theodore Wai} and Esther Ooi and Gerald Watts and Dick Chan and P.J. Meikle and Hugh Barrett",
    year = "2015",
    month = "6",
    doi = "10.1210/jc.2014-4348",
    language = "English",
    volume = "100",
    pages = "2497--2501",
    journal = "Journal of Endocrinology & Metabolism",
    issn = "0021-972X",
    publisher = "ENDOCRINE SOC",
    number = "6",

    }

    TY - JOUR

    T1 - Association of plasma ceramides and sphingomyelin with VLDL apoB-100 fractional catabolic rate before and after rosuvastatin treatment

    AU - Ng, Theodore Wai

    AU - Ooi, Esther

    AU - Watts, Gerald

    AU - Chan, Dick

    AU - Meikle, P.J.

    AU - Barrett, Hugh

    PY - 2015/6

    Y1 - 2015/6

    N2 - Copyright © 2015 by the Endocrine Society. Introduction: The objective of the study was to examine post hoc associations between plasma sphingolipids and lipoprotein kinetics in men with the metabolic syndrome after rosuvastatin treatment. Materials and Methods: Plasma sphingolipid profiling, determined by tandem mass spectrometry, was performed in a randomized, double-blind, triple-crossover trial (n = 12) of 5-week treatment periods with placebo or rosuvastatin (10 or 40 mg/d) with 2-week washouts between treatments. Results and Discussion: Baseline plasma ceramides were associated with very low-density lipoprotein (VLDL) apolipoprotein (apo)-B-100 concentration (r = 0.58, P <.05) and inversely with VLDL apoB-100 fractional catabolic rate (FCR; r = -0.67, P = .02). Posttreatment changes with rosuvastatin (40 mg/d) in plasma ceramides were inversely associated with VLDL apoB-100 FCR (r = -0.62, P = .03) independent of changes in plasma triglycerides, cholesterol, and low-density lipoproteincholesterol. By contrast, baseline and postrosuvastatin treatment plasma sphingomyelin levels were not associated with apoB-100 kinetics. Plasma ceramides and sphingomyelin were not associated with the kinetics or concentrations of high-density lipoprotein apoA-I, and low-density lipoprotein apoB. In the metabolic syndrome, the ability of rosuvastatin to increase VLDL apoB-100 FCR may reflect ceramide-specific mechanistic actions and/or sphingolipid exchange.

    AB - Copyright © 2015 by the Endocrine Society. Introduction: The objective of the study was to examine post hoc associations between plasma sphingolipids and lipoprotein kinetics in men with the metabolic syndrome after rosuvastatin treatment. Materials and Methods: Plasma sphingolipid profiling, determined by tandem mass spectrometry, was performed in a randomized, double-blind, triple-crossover trial (n = 12) of 5-week treatment periods with placebo or rosuvastatin (10 or 40 mg/d) with 2-week washouts between treatments. Results and Discussion: Baseline plasma ceramides were associated with very low-density lipoprotein (VLDL) apolipoprotein (apo)-B-100 concentration (r = 0.58, P <.05) and inversely with VLDL apoB-100 fractional catabolic rate (FCR; r = -0.67, P = .02). Posttreatment changes with rosuvastatin (40 mg/d) in plasma ceramides were inversely associated with VLDL apoB-100 FCR (r = -0.62, P = .03) independent of changes in plasma triglycerides, cholesterol, and low-density lipoproteincholesterol. By contrast, baseline and postrosuvastatin treatment plasma sphingomyelin levels were not associated with apoB-100 kinetics. Plasma ceramides and sphingomyelin were not associated with the kinetics or concentrations of high-density lipoprotein apoA-I, and low-density lipoprotein apoB. In the metabolic syndrome, the ability of rosuvastatin to increase VLDL apoB-100 FCR may reflect ceramide-specific mechanistic actions and/or sphingolipid exchange.

    U2 - 10.1210/jc.2014-4348

    DO - 10.1210/jc.2014-4348

    M3 - Article

    VL - 100

    SP - 2497

    EP - 2501

    JO - Journal of Endocrinology & Metabolism

    JF - Journal of Endocrinology & Metabolism

    SN - 0021-972X

    IS - 6

    ER -